Software company DocuSign’s (DOCU) stock scored a rating upgrade from Hold to Buy from William Blair, thanks to the optimism ...
Emerging markets present a landscape of opportunity for equity investors despite macroeconomic headwinds. Click to read.
Confluent (NASDAQ:CFLT – Get Free Report)‘s stock had its “outperform” rating reissued by analysts at William Blair in a ...
The biotech is exploring opportunities for a reverse merger or other business combinations. CFO and now interim CEO Anup ...
1d
Fintel on MSNWilliam Blair Upgrades DocuSign (DOCU)Fintel reports that on March 17, 2025, William Blair upgraded their outlook for DocuSign (NasdaqGS:DOCU) from Market Perform ...
1d
Fintel on MSNWilliam Blair Initiates Coverage of Butterfly Network (BFLY) with Outperform RecommendationFintel reports that on March 17, 2025, William Blair initiated coverage of Butterfly Network (NYSE:BFLY) with a Outperform ...
Analysts at William Blair lowered their Q1 2025 earnings estimates for Legend Biotech in a research report issued to clients ...
JPMorgan Chase & Co. has hired William Kallop from William Blair & Co. for its mergers and acquisitions group focused on ...
William Blair analyst Matthew Phipps last night upgraded Genmab (GMAB) to Outperform from Market Perform without a price target. after the ...
Investing.com -- William Blair analysts issued a cautionary note on Palantir Technologies (NASDAQ:PLTR), highlighting potential downside risk for the stock despite continued commercial momentum.
The firm upgraded Palantir from Underperform to Market Perform after a sharp stock decline but did not assign a price target.
The embedded finance company, which posted a loss last year, hired Citi to explore its strategic options and named an interim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results